It was publicized today how a Swiss pharmaceutical firm that generates quality cancer care products as well as rare ailments products, Helsinn has appointed Lonnie Moulder and Eric Cornut to the Helsinn Group’s Board of Directors.
Eric Cornut has previously been a part of the Helsinn Group Board when he held a Board role from 2017’s May to 2018’s October. Eric Cornut has more than 27 years of experience in pharmaceutical management. He has previously acted as the European Federation of Pharmaceutical Industries and Associations’ Interim Director-General. At the European Federation of Pharmaceutical Industries and Associations, he used to be the Chairman of their executive committee for half a decade. Before this, he spent more than 2 decades at Novartis AG in numerous high-profile posts, such as Chief Commercial Officer at Novartis Pharma AG, etc. Presently, he is among the members of the Supervisory Board at Stada AG and Menarini’s Group Chairman. From the University of Basel, Switzerland, he holds a Doctoral degree in Law, as well as a Master of Law degree from the University of California, Berkeley, in the U.S.
On the other hand, Lonnie Moulder has considerable experience of more than 3 decades as a leader and Board level advisor. Recently, he was the chief executive officer of Tesaro, Inc. Tesoro is a biopharmaceutical of which he is a cofounder and was acquired last year by GlaxoSmithKline for $5.1 billion. He has also acted as the chief executive officer of MGI PHARMA. MGI PHARMA was purchased for $3.9 billion by Eisai Co., Ltd. in 2008. He has acted as the chief executive officer of Abraxis BioScience, Inc. as well.
Presently, Lonnie Moulder is Tellus BioVentures’ Founding General Partner. Moulder is also an active member of Temple University’s Board of Trustees